Management of Diabetes Mellitus Patients With Retinopathy

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00828425
First received: January 23, 2009
Last updated: August 17, 2010
Last verified: August 2010
  Purpose

Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland. Following elements are going to be analyzed:

  • which medication are used to keep blood pressure under control?
  • which medication are used for metabolic control?
  • the average control level of metabolism and blood pressure is compliant with the international guidelines?
  • laser photocoagulation plays a role in the control of metabolism and blood pressure?
  • there are differences in the control of metabolism and blood pressure between patients with DM I or DM II?
  • there is an influence of renal failure on the choose of medication?

Condition
Retinopathy
Diabetes Mellitus

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Management of Diabetes Mellitus Patients With Retinopathy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Blood lipids, glycemia, HbA1C, blood creatinine, proteinuria, body weight [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
  • evolution of diabetic retinopathy [ Time Frame: every 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • concomitant medication [ Time Frame: every 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: December 2008
Study Completion Date: August 2009
Groups/Cohorts
1
Diabetic patients with retinopathy

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Diabetic patients with diabetic retinopathy

Criteria

Inclusion Criteria:

  • Diabetic patients
  • Diabetic retinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00828425

  Show 62 Study Locations
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: Dr. Med. Dirk Schneider - Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00828425     History of Changes
Other Study ID Numbers: NIS-CCH-DUM-2008/1
Study First Received: January 23, 2009
Last Updated: August 17, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by AstraZeneca:
Diabetes Mellitus
retinopathy
Management of diabetic patients with retinopathy

Additional relevant MeSH terms:
Diabetes Mellitus
Retinal Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Eye Diseases

ClinicalTrials.gov processed this record on August 28, 2014